Kiss Evelin, Simon Zsófia, Illés Árpád, Jóna Ádám
Department of Hematology, Faculty of Medicine, University of Debrecen, 4032 Debrecen, Hungary.
Doctoral School of Clinical Medicine, University of Debrecen, 4032 Debrecen, Hungary.
Cancers (Basel). 2024 Dec 29;17(1):73. doi: 10.3390/cancers17010073.
: Follicular lymphoma (FL) is a heterogeneous disease, and identifying high-risk patients early is crucial for optimal management. This study aimed to evaluate the prognostic significance of interim positron emission tomography/computed tomography (PET/CT) in newly diagnosed FL patients undergoing first-line treatment. : This single-center, retrospective study included 103 patients with newly diagnosed FL who underwent interim PET/CT. The primary endpoint was progression-free survival (PFS). The prognostic value of positive interim PET/CT, Deauville scores, and maximum standardized uptake values (SUVmax) were analyzed among other clinical features. : A total of 30 patients (29.1%) were deemed interim PET/CT-positive. The interim PET/CT-positive group demonstrated a significantly shorter median PFS compared to the interim PET/CT-negative group (17 months vs. not reached, respectively; < 0.0001). Similarly, patients with Deauville scores of 1-3 had better PFS, with median survival not yet reached, while those with higher Deauville scores exhibited poorer progression-free survival and a median survival of 18 months. Notably, patients with an interim PET/CT SUVmax exceeding 3.365 experienced significantly shorter median survival compared to those with lower values. : Our findings support the use of interim PET/CT as a prognostic tool in FL. These results are consistent with other studies, although some debate exists regarding the optimal PET/CT metric. Further research is needed to validate these findings and explore personalized treatment strategies based on interim PET/CT results.
滤泡性淋巴瘤(FL)是一种异质性疾病,早期识别高危患者对于优化治疗至关重要。本研究旨在评估中期正电子发射断层扫描/计算机断层扫描(PET/CT)在新诊断的接受一线治疗的FL患者中的预后意义。 :这项单中心回顾性研究纳入了103例新诊断的接受中期PET/CT检查的FL患者。主要终点是无进展生存期(PFS)。分析了中期PET/CT阳性、Deauville评分和最大标准化摄取值(SUVmax)与其他临床特征相比的预后价值。 :共有30例患者(29.1%)被判定为中期PET/CT阳性。与中期PET/CT阴性组相比,中期PET/CT阳性组的中位PFS显著缩短(分别为17个月和未达到;<0.0001)。同样,Deauville评分为1-3分的患者PFS较好,中位生存期尚未达到,而Deauville评分较高的患者无进展生存期较差,中位生存期为18个月。值得注意的是,中期PET/CT SUVmax超过3.365的患者中位生存期明显短于SUVmax较低的患者。 :我们的研究结果支持将中期PET/CT作为FL的预后工具。这些结果与其他研究一致,尽管关于最佳PET/CT指标存在一些争议。需要进一步研究来验证这些发现,并探索基于中期PET/CT结果的个性化治疗策略。